Following publication in 2004, as practitioners realized the effect of the revised, now-enforceable General Chapter ‹797›
on their daily work, there was a surge of input that had not initially been solicited— about 2000 comments. This outpouring
underscored the importance of public comment as well as expert review, and USP started the current revision cycle as quickly
as possible. This time we did it quite differently: We held briefings for 16 stakeholder organizations, plus a stakeholder
forum meeting. About 60 compounding professionals and other interested parties attended, and we held Webinars for those who
could not be there in person. At these sessions, staff reviewed proposed changes and actively sought stakeholder input. In
addition, we provided an online mechanism to view and comment on proposed changes to ‹797›. Through these outreach efforts,
we got hundreds of comments that went into the revision process.
This marked a first-time, singular outreach program for USP. Why did we go to such lengths? In short, the response of the
compounding community to the initial lack of inclusion reminded USP-staff and volunteer experts alike that not actively providing
channels for public comment is neither in the interest nor the tradition of USP standards setting. The current revision cycle
of General Chapter ‹797›, based on extensive interactions among USP staff, volunteer experts, and the compounding community,
is fully supportive of USP's core mission of objective science and transparency. Inclusion can sometimes be messy and it can
take time—you'll note that ‹797› has yet to be finalized in official publication. But it will be published, as a result of
the kind of dialogue between public and experts that has characterized USP standards setting for nearly 200 years.
I urge members of the extended pharmaceutical community to participate in this well-established, respected, and effective
process. Thorough instructions are available on the USP Web site, at
http://www.usp.org/USPNF/, and a diagram illustrating the standards revision process is published in the front matter of every issue of Pharmacopeial Forum. Your participation will help keep the process a model of scientific integrity, thereby helping to ensure good pharmaceutical
care for all.
Todd L. Cecil is the vice-president of the Department of Standards Division at the US Pharmacopeia, email@example.com